早发性结直肠癌患者中胚系癌症易感基因突变的患病率与谱系
该研究前瞻性纳入51家医院的450例50岁以下结直肠癌患者,采用二代测序检测25个癌症易感基因。72例(16%)发现基因突变,其中33.3%突变阳性者不符合既有基因检测标准。作者认为可考虑对所有早发性结直肠癌患者进行多基因panel遗传咨询和检测。
要点
- 450例早发性结直肠癌患者中72例(16%)检出癌症易感基因突变。
- 72例突变阳性者中24例(33.3%)不符合既有基因检测标准。
- 作者认为可考虑对所有早发性结直肠癌患者进行多基因panel遗传咨询和检测。
核心结论
- 450例早发性结直肠癌患者中72例(16%)存在基因突变,突变频率高且谱系广,作者认为可考虑对所有早发性结直肠癌患者进行多基因panel遗传咨询和检测。
研究设计与样本
- 前瞻性研究,自2013年1月1日至2016年6月20日从51家医院纳入450例50岁以下结直肠癌患者进入Ohio Colorectal Cancer Prevention Initiative。
- 通过微卫星不稳定性检测和/或免疫组化判定错配修复(MMR)缺陷,采用二代测序检测胚系DNA中25个癌症易感基因的突变。
主要发现
- 450例患者共发现75个基因突变,分布于72例(16%)患者。
- 48例(10.7%)为MMR缺陷肿瘤,其中40例(83.3%)至少携带1个基因突变:37例为Lynch综合征(13例MLH1,含1例胚系MLH1甲基化;16例MSH2;1例MSH2/单等位MUTYH;2例MSH6;5例PMS2)。
- MMR缺陷组中1例携带APC c.3920T>A,p.I1307K突变及PMS2变异,9例(18.8%)为双体细胞MMR突变(含2例胚系双等位MUTYH突变),1例为体细胞MLH1甲基化。
- 402例(89.3%)为MMR功能正常肿瘤,其中32例(8%)至少携带1个基因突变:9例为高外显率结直肠癌基因突变(5例APC;1例APC/PMS2;2例双等位MUTYH;1例SMAD4),13例为传统上与结直肠癌无关的高或中外显率基因突变(3例ATM;1例ATM/CHEK2;2例BRCA1;4例BRCA2;1例CDKN2A;2例PALB2),10例为低外显率结直肠癌基因突变(3例APC c.3920T>A,p.I1307K;7例单等位MUTYH)。
- 72例突变阳性患者中24例(33.3%)不符合针对其所携突变基因的既有基因检测标准。
临床怎么用
- 作者认为,鉴于突变频率高且谱系广,可考虑对所有早发性结直肠癌患者进行多基因panel遗传咨询和检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. OBJECTIVE: To determine the frequency and spectrum of cancer susceptibility gene mutations among patients with early-onset CRC. DESIGN, SETTING, AND PARTICIPANTS: Overall, 450 patients diagnosed with colorectal cancer younger than 50 years were prospectively accrued from 51 hospitals into the Ohio Colorectal Cancer Prevention Initiative from January 1, 2013, to June 20, 2016. Mismatch repair (MMR) deficiency was determined by microsatellite instability and/or immunohistochemistry. Germline DNA was tested for mutations in 25 cancer susceptibility genes using next-generation sequencing. MAIN OUTCOMES AND MEASURES: Mutation prevalence and spectrum in patients with early-onset CRC was determined. Clinical characteristics were assessed by mutation status. RESULTS: In total 450 patients younger than 50 years were included in the study, and 75 gene mutations were found in 72 patients (16%). Forty-eight patients (10.7%) had MMR-deficient tumors, and 40 patients (83.3%) had at least 1 gene mutation: 37 had Lynch syndrome (13, MLH1 [including one with constitutional MLH1 methylation]; 16, MSH2; 1, MSH2/monoallelic MUTYH; 2, MSH6; 5, PMS2); 1 patient had the APC c.3920T>A, p.I1307K mutation and a PMS2 variant; 9 patients (18.8%) had double somatic MMR mutations (including 2 with germline biallelic MUTYH mutations); and 1 patient had somatic MLH1 methylation. Four hundred two patients (89.3%) had MMR-proficient tumors, and 32 patients (8%) had at least 1 gene mutation: 9 had mutations in high-penetrance CRC genes (5, APC; 1, APC/PMS2; 2, biallelic MUTYH; 1, SMAD4); 13 patients had mutations in high- or moderate-penetrance genes not traditionally associated with CRC (3, ATM; 1, ATM/CHEK2; 2, BRCA1; 4, BRCA2; 1, CDKN2A; 2, PALB2); 10 patients had mutations in low-penetrance CRC genes (3, APC c.3920T>A, p.I1307K; 7, monoallelic MUTYH). Importantly, 24 of 72 patients (33.3%) who were mutation positive did not meet established genetic testing criteria for the gene(s) in which they had a mutation. CONCLUSIONS AND RELEVANCE: Of 450 patients with early-onset CRC, 72 (16%) had gene mutations. Given the high frequency and wide spectrum of mutations, genetic counseling and testing with a multigene panel could be considered for all patients with early-onset CRC.
引用
- Pearlman R, Frankel WL, Swanson B, et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017. PMID: 27978560. doi:10.1001/jamaoncol.2016.5194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。